Clinical trials
Alzheimer s Disease clinical trials
Below are recruiting alzheimer s disease clinical trials, each written for real people, not researchers. We’re tracking 600 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT02800395Recruiting
Study links brain changes to diet and blood markers in Alzheimer’s
This study looks at how diet-related and blood “stress” markers relate to how thinking and memory decline over time in people with Alzheimer’s. It may help researchers find useful biomarkers to better track progression and guide future care.
Pierre-BéniteAges 55 years+ - NCT05315895Recruiting
Study of people with “dampness” signs in Chinese medicine
This is an observational study that looks at a Chinese-medicine pattern called “dampness” by collecting health and biological information from volunteers. It may help researchers better understand what this pattern looks like and how it relates to people’s health.
Guangzhou, GuangdongAges 35–79 - NCT03621839Recruiting
Study of new spinal-fluid tests for Alzheimer’s disease
This study looks at new test markers found in spinal fluid to help with diagnosing Alzheimer’s disease. If you are already getting a spinal-fluid sample as part of your dementia workup, this trial may check it for additional information.
Nancy, Grand EstAges Any age - NCT07842146Recruiting
Urolithin a for people with alzheimer's disease
This study tests a dietary supplement called Urolithin A (Mitopure®) to see if it helps people with mild-to-moderate Alzheimer's disease. You would take the supplement or a placebo, and researchers will track your memory and daily function over time.
PragueAges 55–85 - NCT07839650Recruiting
Brain stimulation and memory training for mild Alzheimer's disease
This study tests whether a painless brain stimulation technique (called tACS) combined with computer-based memory exercises can improve thinking and memory in people with mild Alzheimer's disease. Participation involves using the stimulation device at home with the help of a trained caregiver.
Brescia, BresciaAges 18 years+ - NCT07803055Recruiting
Blood test for early signs of Alzheimer's disease
This study looks at tiny particles in the blood that may show early signs of Alzheimer's disease. It aims to help with earlier diagnosis and monitoring, which could lead to better care and treatment opportunities.
RomeAges 55–80 - NCT07786116Recruiting
Gut bacteria in Parkinson's disease and related conditions
This study looks at how certain gut bacteria (methanogens) are involved in the progression of Parkinson's disease and related conditions. It aims to understand the connection between gut health and brain health, which may lead to better treatments.
Cambridge, CB2Ages 55 years+ - NCT07768579Recruiting
Sequential treatment for Alzheimer's disease
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
Beijing, Beijing MunicipalityAges 55–85 - NCT07741071RecruitingPhase 2
Vitamin B3 supplement for early Alzheimer's disease
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
BergenAges 50–85 - NCT05711888Recruiting
Alzheimer brain study using a memory and recognition task
This study uses a computer task to test thinking and recognition skills in people with or without Alzheimer’s disease. It also includes checking Alzheimer-related biomarkers to help researchers understand how the task connects to the disease.
Beşiktaş, IstanbulAges Any age - NCT07724132RecruitingPhase 3
Treatments for sustained response in Alzheimer's disease
This study tests whether a treatment (atomoxetine or metformin) can help people with Alzheimer's disease maintain an improved state for at least 18 months. It may help you or a loved one stabilize symptoms and slow disease progression.
CambridgeAges 55 years+ - NCT07693140RecruitingPhase 1/Phase 2
Low-dose radiation therapy for Alzheimer's disease
This trial tests if very low doses of radiation to the brain can reduce inflammation and slow memory loss in people with Alzheimer's or similar dementias. It involves monthly clinic visits for a year.
Winter Park, FloridaAges 50 years+ - NCT07680335Recruiting
Blood test to help diagnose Alzheimer's earlier
This study is testing whether a simple blood test can help doctors diagnose Alzheimer's disease earlier and more accurately. It's for people who are having memory or thinking problems and are visiting a memory clinic.
Amsterdam, North HollandAges 55 years+ - NCT07688213RecruitingPhase 2
Study of an investigational drug for early Alzheimer's disease
This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.
Oakland, CaliforniaAges 55–85 - NCT07672977Enrolling by invitation
Sound therapy at home to improve deep sleep in early Alzheimer's
This study tests whether a wearable device that plays soft sounds during sleep can boost deep sleep brain waves in people with mild memory problems caused by Alzheimer's. It aims to see if this simple, home-based approach can help protect memory and thinking.
Zaragoza, ZaragozaAges 50–75 - NCT07667478Recruiting
Brain stimulation study for early Alzheimer's memory loss
This study tests whether a non-invasive magnetic brain stimulation technique can help improve memory in people with early Alzheimer's disease. It may be an option if you have mild cognitive impairment or mild dementia due to Alzheimer's and have had a positive blood test for Alzheimer's markers.
Houston, TexasAges 55–90 - NCT07604896RecruitingPhase 4
Lecanemab for early Alzheimer's disease with amyloid buildup
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Wenzhou, ZhejiangAges 50–90 - NCT07553338RecruitingPhase 2
Leronlimab Safety and Brain Inflammation in Alzheimer's
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
New York, New YorkAges 50 years+ - NCT07467460Recruiting
Precision medicine trial for Parkinson's and Alzheimer's
This trial uses advanced tools to better diagnose and treat Parkinson's disease and Alzheimer's disease. It aims to personalize care based on your specific symptoms and biomarkers.
PozzilliAges 18 years+ - NCT07367815RecruitingPhase 1/Phase 2
Stem cells from fat tissue for Alzheimer's disease
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
ToulouseAges 50–85 - NCT06850597RecruitingPhase 2
Testing dimethyl fumarate for early Alzheimer's disease
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
Lodz, Łódź VoivodeshipAges 55–90 - NCT06203106Recruiting
NYSCF Scientific Discovery Biobank
This study collects blood, saliva, or skin samples from people with certain neurological conditions and from healthy volunteers to help researchers better understand and find treatments for these diseases.
New York, New YorkAges 4 weeks+ - NCT06852352Recruiting
Modified brain lymph surgery for Alzheimer's or Parkinson's
This study tests a new, less invasive surgery to improve lymph drainage from the brain. It may help clear harmful proteins linked to Alzheimer's or Parkinson's disease.
Hangzhou, ZhejiangAges 50–80 - NCT06619613RecruitingPhase 1
Study of CM383 for early Alzheimer's disease
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
HefeiAges 50–85
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer s disease?
- Yes. Clin2 currently lists 600 recruiting alzheimer s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.